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Abstract
Background The efﬁcacy of low-dose lansoprazole has
not been established for the prevention of recurrent gastric
or duodenal ulcers in those receiving long-term low-dose
aspirin (LDA) for cardiovascular and cerebrovascular
protection. This study sought to examine the efﬁcacy of
low-dose lansoprazole (15 mg once daily) for the second-
ary prevention of LDA-associated gastric or duodenal
ulcers.
Methods Patients were randomized to receive lansopraz-
ole 15 mg daily (n = 226) or gefarnate 50 mg twice daily
(n = 235) for 12 months or longer in a prospective, mul-
ticenter, double-blind, randomized active-controlled trial,
followed by a 6-month follow-up study with open-label
lansoprazole treatment. The study utilized 94 sites in Japan
and 461 Japanese patients with a history of gastric or
duodenal ulcers who required long-term LDA therapy for
cardiovascular and cerebrovascular disease.
Results The primary endpoint was the development of
gastric or duodenal ulcers. The cumulative incidence of
gastric or duodenal ulcers on days 91, 181, and 361 from
the start of the study was calculated by the Kaplan–Meier
method as 1.5, 2.1, and 3.7%, respectively, in the lansop-
razole group versus 15.2, 24.0, and 31.7%, respectively, in
the gefarnate group. The risk of ulcer development was
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DOI 10.1007/s00535-011-0397-7signiﬁcantly (log-rank test, P\0.001) lower in the lan-
soprazole group than in the gefarnate group, with the
hazard ratio being 0.099 (95% conﬁdence interval [CI]
0.042–0.230).
Conclusion Lansoprazole was superior to gefarnate in
reducing the risk of gastric or duodenal ulcer recurrence in
patients with a deﬁnite history of gastric or duodenal ulcers
who required long-term LDA therapy.
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ulcers  Lansoprazole  Cardiovascular diseases 
Cerebrovascular diseases
Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs), including
low-dose aspirin (LDA), are known to disrupt the mucosal
resistance to gastric acid through mechanisms including the
decreased production of endogenous prostaglandin in the
gastric mucosa, and are thus associated with adverse events
such as gastric or duodenal ulcers. In one Japanese study of
patients presenting with a bleeding ulcer, 7.6% were taking
LDA [1]. Another study found the point prevalence of
ulcers in LDA users to be 11.9–15.2%, irrespective of the
aspirin formulation [2]. Furthermore, several observational
studies have suggested that the increasing use of LDA is
becoming a major cause of bleeding ulcers [3]. In a Japa-
nese single-institution report, ulcer lesions were endo-
scopically identiﬁed in 38 (12.4%) of 305 patients taking
LDA [4].
When patients present with gastrointestinal bleeding,
discontinuation of LDA is recommended according to
various guidelines [5]. However, discontinuation of LDA
can be associated with a recurrence of disease, and this can
result in serious outcomes [6]. Thus, it is vitally important
to ensure prophylaxis of gastric or duodenal ulcers in
patients on LDA therapy.
In this context, a number of controlled studies have
reported on the prevention of gastric or duodenal ulcers
with regular-dose H2-receptor antagonists or proton pump
inhibitors (PPIs) in patients during LDA therapy [7–10].
Based on the evidence obtained to date, a clinical expert
consensus statement [5] recommends PPIs as the preferred
agents for the prophylaxis of LDA-associated gastrointes-
tinal injury. However, to date, low-dose lansoprazole has
not been evaluated in a clinical trial for its prophylactic
efﬁcacy in patients with deﬁnitive evidence of previous
ulcer development.
This study thus aimed to examine the preventive effect
of low-dose lansoprazole (15 mg daily) against the recur-
rence of gastric or duodenal ulcer associated with long-
term LDA therapy in patients with deﬁnitive evidence of
previous ulcer history. Ulcer recurrence was deﬁned as
endoscopically conﬁrmed ulcers, and the occurrences of
gastric or duodenal bleeding with or without hospitaliza-
tion were also evaluated. Appendix 1 shows the list of
investigators for the Lansoprazole Ulcer Prevention Study
Group (low-dose aspirin therapy).
Given that no drug has been proven to be effective for the
preventionof gastric orduodenalulcer associated withLDA
therapy in Japan, and given that it is unethical to conduct a
placebo-controlled trial in patients at high risk of develop-
ing gastric or duodenal ulcers, the present study was
designed to compare the efﬁcacy of lansoprazole 15 mg
once daily and gefarnate 50 mg twice daily [11, 12].
Gefarnate is a cytoprotective anti-ulcer agent which is
approved for the treatment for gastric or duodenal ulcers.
These cytoprotective anti-ulcer agents are commonly
prescribedasprophylacticdrugs toreduceNSAID- orLDA-
induced gastrointestinal injury, although they have not been
investigated in a controlled trial for the latter indication.
Methods
Design overview
The study protocol was approved by the Ethics Committee
of each participating institution, and all patients gave
written informed consent to participate in the study. The
Independent Data Monitoring Committee planned an
interim analysis in advance to investigate whether or not to
continue the study on the basis of interim efﬁcacy and
safety ﬁndings, based on the predeﬁned criteria. An inde-
pendent statistician performed the interim analysis on
behalf of the Independent Data Monitoring Committee.
After the committee made the decision to discontinue the
double-blind trial, the patients at the 68 participating
healthcare institutes were invited to move on to the follow-
up trial with open-label lansoprazole treatment lasting up to
6 months. This trial was registered with ClinicalTrials.gov,
number NCT00762359.
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123Setting and participants
Patients were enrolled in the study if they met the fol-
lowing criteria: those who were being given LDA when
they gave informed consent, and who required long-term
LDA therapy after the start of the study (day 1) with the
investigational drug; and those in whom a history of gastric
or duodenal ulcer (or gastroduodenal ulcer) was conﬁrmed
by endoscopy, i.e., those who were conﬁrmed to have an
ulcer scar on day 1 or were conﬁrmed to have an ulcer or
ulcer scar in an endoscopic examination performed prior to
day 1 (e.g., photographs, ﬁlms).
Patients were excluded if they were conﬁrmed to have
an open gastric or duodenal ulcer or an active upper gas-
trointestinal hemorrhage by endoscopy on day 1; aspirin-
induced asthma or hypersensitivity to NSAIDs including
aspirin, or a history of hypersensitivity; a history of sur-
gery or a planned operation which affects gastric secretion
(e.g., upper gastrointestinal tract resection, vagotomy);
clinically signiﬁcant liver or kidney disorder (including
liver tests demonstrating aspartate aminotransferase
[AST]/alanine aminotransferase [ALT] values 2.5 times or
higher than their upper limit of normal, or creatinine levels
2.0 times or higher than its upper limit of normal); or an
active cancer.
All patients conﬁrmed to be eligible at each trial site
were reassessed for their eligibility, based either on endo-
scopic images on ﬁlms or data submitted after randomi-
zation, by an independent panel of expert endoscopists.
Randomization and intervention
Patients who met the inclusion criteria were randomly
assigned to one of the following two treatment groups: a
group receiving the investigational drug (lansoprazole
15 mg orally given once daily) and the cytoprotective
anti-ulcer agent, gefarnate placebo (twice daily) or a
group receiving gefarnate [11, 12] (50 mg orally given
twice daily) and a lansoprazole placebo (once daily), in
combination with LDA (81–324 mg given once daily) for
a duration of 12 months or longer (up to 30 months).
Lansoprazole and gefarnate placebos were used to ensure
that all patients followed the same regimen and that
blinding was maintained. The treatment-group assignment
was done by computer-generated random sequence num-
bers. Patients were randomly assigned by investigators to
receive lansoprazole or gefarnate at a 1:1 ratio according
to the unique sequential numbers for the study drugs,
which were pre-assigned to each study site before the
start of the treatment. When the onset of ulcer was
diagnosed endoscopically or LDA was changed to dif-
ferent drugs, the subjects were excluded from the study at
that time point.
Outcomes and measurements
The primary endpoint was the recurrence of gastric or
duodenal ulcers, deﬁned as patients conﬁrmed to have
active-stage or healing-stage ulcers associated with a
mucosal defect with whitish exudates measuring 3 mm or
greater. All ulcers conﬁrmed on endoscopy and reported
from each study site were reconﬁrmed by the independent
expert panel, based on submitted ﬁlms. The secondary
endpoints were the development of gastric and/or duodenal
hemorrhagic lesions as observed with endoscopy, treatment
discontinuations due to lack of efﬁcacy, gastric and/or
duodenal mucosal damage as assessed with a modiﬁed
Lanza score [13], and gastrointestinal symptoms.
Follow-up procedures
Endoscopy was scheduled every 12 weeks until 12 months
of treatment and every 24 weeks after 12 months. Non-
scheduled endoscopy was also performed if patients were
suspected of having symptoms associated with ulcers or
signs and symptoms indicative of gastrointestinal bleeding.
Every 4 weeks, clinical laboratory tests (chemistry,
hematology, and urinalysis) were performed, blood pressure
was measured, compliance checks (returned tablet counts)
were conducted, and patients were asked about any adverse
effects they experienced. All patients were scheduled to
receive the study treatments in a double-blind fashion until
12 months after the start of the study in the last enrolled
patient. After the termination of the double-blind trial,
patients at the 68 study sites were invited to participate in
the follow-up study, in which all patients were treated once
daily with lansoprazole 15 mg. If onset of an ulcer was
conﬁrmed on endoscopy in a patient, the patient discon-
tinued their medication, and antiulcer treatment – such as
full-dose PPI therapy – was offered for ulcer healing.
Statistical analysis
The 1-year cumulative incidences of ulcer events in
patients treated with lansoprazole and gefarnate, in addi-
tion to LDA therapy, were assumed to be 6 and 13%,
respectively, which suggested that the hazard ratio (HR) of
the lansoprazole-treated group relative to the gefarnate-
treated group was 0.44 under an exponential assumption of
event distributions. We required a total of 64 ulcer events
(endpoints) for the two treatment groups to ensure a sta-
tistical power of 90% using a log-rank test with a two-sided
alpha of 5%. To observe 64 events, we required the
enrollment of 406 patients for each treatment group at
randomization, for a total of 812 patients for the study,
assuming a mean follow-up duration of 1 year and a 1-year
dropout rate of 20%.
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123One interim analysis was planned in advance for the
Independent Data Monitoring Committee to perform when
halfoftherequirednumberofulcereventswasobserved.The
O’Brien-Flemingboundary,basedontheinformationfraction
of 0.5, was employed for an overall signiﬁcance level of
a = 0.05. To avoid unnecessary trial hazard to subjects
assigned to either arm, we planned to discontinue the double-
blind trial if the difference in the primary endpoint reached
signiﬁcance at P = 0.0038 at the interim analysis.
The cumulative incidences of the primary and secondary
endpoints were estimated by using the Kaplan–Meier
method and compared between the treatment groups by
using the log-rank test. For event-free cases the event times
were censored either at the point of the last endoscopy
performed or at the point of early withdrawal. We also
performed multivariate Cox regression analyses to adjust
for possible effects of baseline variables on event times.
The ﬁnal analyses were conducted for the full-analysis set
(FAS), deﬁned as all patients who were randomized and
received one or more doses of the study medication. In the
survival analysis, the patients at risk were deﬁned as all
event-free FAS patients who had at least one post-ran-
domization assessment with endoscopy.
Differences in adverse events between the lansoprazole
and gefarnate groups were tested for signiﬁcance by using
the v
2 test.
Analyses were conducted using SAS software (version
9.1.3; SAS Institute, Cary, NC, USA). One and the same
statistician (S.M.) had full access to all the trial data and
conducted statistical analyses independently of the spon-
soring company.
Role of the funding source
Takeda Pharmaceutical Company Limited (the Sponsor)
and its contractor provided all ﬁnancial and material sup-
port for the study design, data collection, data analysis,
data interpretation, and preparation and review of manu-
scripts. The Sponsor was also responsible for consultations
with the authors and the members of this study group about
the study design and about monitoring of the study. The
principal investigator (K.S.) was responsible for the study
design and for preparation of the manuscript. All co-
authors reviewed the manuscript, and necessary revisions
were made to accommodate their suggestions and opinions.
Results
Study patients
This prospective, double-blind, randomized, active-con-
trolled trial with an open-label 6-month follow-up study
was conducted at a total of 94 healthcare institutions in
Japan, in accordance with the principles of good clinical
practice and the Declaration of Helsinki. The Independent
Data Monitoring Committee performed an interim analysis,
based on data that had become available from 414 patients.
The cumulative number of ulcer events at the interim
analysis was 30 in the gefarnate group and three in the
lansoprazole group. The HR was estimated as 0.080 (95%
CI 0.023–0.264; P\0.001, 2-sided log-rank test), verify-
ing the efﬁcacy of lansoprazole compared with gefarnate
and, accordingly, the Independent Data Monitoring Com-
mittee made the decision to terminate the initial part of the
study early. Data completion and analysis were performed
based on data collected at the termination of the trial. The
results discussed here are based on the ﬁnal data.
Figure 1 shows the ﬂow diagram of this trial. Of the 771
patients enrolled, 461 patients were randomized, while the
remaining 310 patients were excluded, primarily because
they were not conﬁrmed to have evidence of past gastric or
duodenal ulcers on baseline endoscopy after enrollment. Of
the 461 patients randomized, 226 were assigned to receive
lansoprazole and 235 to receive gefarnate. Of the 235
patients assigned to gefarnate, the study medication was
not given to one patient, because malignancy was found in
this patient (a violation of the study protocol). Thus, the
FAS population comprised a total of 460 patients, with 226
and 234 patients in the lansoprazole group and the gefar-
nate group, respectively. The numbers of withdrawals were
similar in the treatment groups, with 59 withdrawals
(26.1%) in the lansoprazole group and 57 (24.3%) in the
gefarnate group. The most frequent reasons for withdrawal
were adverse events, which occurred in 20 (33.9%) patients
in the lansoprazole group and 23 (40.4%) patients in the
gefarnate group; followed by protocol deviations (includ-
ing failure to take the medication) and consent withdrawals
in 21 (35.6%) and 13 (22.0%) patients in the lansoprazole
group, and 13 (22.8%) and 10 (17.5%) patients, respec-
tively, in the gefarnate group. Additionally, four patients in
the gefarnate group withdrew due to lack of efﬁcacy or
suspected ulcer-related symptoms/diagnoses. The median
duration of follow-up was 7.5 months (range 0.1–17.0) for
the lansoprazole group and 5.7 months (range 0.0–16.5) for
the gefarnate group. Compliance with the study medication
and LDA therapy was similarly high in the two treatment
groups. There was no difference between the treatment
groups in the frequency distribution of baseline variables
(Table 1).
Efﬁcacy
In the FAS population, the cumulative number of gastric or
duodenal ulcer recurrences, i.e., the primary endpoint, at
the end of the study was 6/226 (2.7%) in the lansoprazole
J Gastroenterol (2011) 46:724–735 727
123group and 53/234 (22.6%) in the gefarnate group (Table 2).
The cumulative recurrences on days 91, 181, and 361 from
the start of the study were estimated as 1.5% (95% CI
0.00–3.20), 2.1% (95% CI 0.06–4.08), and 3.7% (95% CI
0.69–6.65), respectively, for the lansoprazole group, com-
pared to 15.2% (95% CI 10.17–20.22), 24.0% (95% CI
17.84–30.21), and 31.7% (95% CI 23.86–39.57), respec-
tively, for the gefarnate group. The HR of the lansoprazole
group relative to the gefarnate group was estimated as
0.099 (95% CI 0.042–0.230)—a 90.1% risk reduction, and
the difference was highly signiﬁcant (log-rank test,
P\0.001) (Table 2; Fig. 2).
As to the secondary endpoints (Table 2), the risk of
developing gastric/duodenal ulcers or hemorrhagic lesions
in the lansoprazole group was signiﬁcantly lower than that
in the gefarnate group (log-rank test, P\0.001). Similarly,
the risk of having gastric/duodenal ulcers, hemorrhagic
lesions, or treatment discontinuations due to lack of efﬁ-
cacy was signiﬁcantly lower in the lansoprazole group than
in the gefarnate group (log-rank test, P\0.001).
The magnitude of risk reduction for gastric or duodenal
ulcers (primary endpoint) was generally stable for all
subgroups as deﬁned by each baseline variable (Table 3).
The analyses in both Helicobacter pylori-positive and
-negative subgroups showed ulcer risk reductions, with an
HR of 0.061 (95% CI 0.019–0.197; P\0.001) and an HR
of 0.206 (95% CI 0.060–0.710; P = 0.02), respectively, in
each of the subgroups in the lansoprazole group as com-
pared to the gefarnate group. Furthermore, the risk reduc-
tion, in terms of HR, was estimated as 0.085 (95% CI
0.034–0.216; P\0.001 by a Wald test) after adjustment
for the baseline variables, H. pylori status, CYP2C19
polymorphism, age, gender, smoking, alcohol consump-
tion, and concomitant use of anticoagulants in a multivar-
iate Cox regression analysis (Table 4).
We also analyzed the sites of the recurrent ulcers to
examine whether the ulcer recurred at sites similar to those
of the scars observed at the start of the study. Whitish or
red scars were reported in 397 patients (86.1% of total). We
further obtained data on the location of the scars from all
59 patients in whom ulcers had relapsed. In 36 (61.0%) of
these patients, ulcer recurrence was observed at sites sim-
ilar to those of the scars seen at the start of the study.
Gastrointestinal damage, as assessed by a modiﬁed
Lanza score [13], from the start of treatment tended to
improve in the lansoprazole group, but to worsen in the
gefarnate group, throughout the course of treatment (Sup-
plemental Fig. 1).
In the FAS population, the cumulative number of
patients who developed gastric or duodenal hemorrhagic
Assessed for eligibility (n = 771) 
Excluded (n = 310) 
♦ No evidence of past ulcer (n = 254) 
♦ Presence of a true ulcer (n = 30) 
♦ Not meeting inclusion criteria (n = 11)
♦ Active gastrointestinal bleedings (n = 6) 
♦ Declined to participate (n = 4) 
♦ Other reasons (n = 5) 
Analyzed (n = 226) 
167 completed study, 59 withdrew: 
20 adverse events 
21 protocol deviations 
13 consent withdrawals 
5 other reasons 
Allocated to lansoprazole (n = 226) 
♦ Received allocated intervention (n = 226)
178 completed study, 57 withdrew: 
23 adverse events 
13 protocol deviations 
10 consent withdrawals 
4 lack of efficacy 
7 other reasons 
Allocated to gefarnate (n = 235) 
♦ Received allocated intervention (n = 234)
♦ Failed to take medication (n = 1)
Analyzed (n = 234)
Allocation
Analysis
Follow-Up
Randomized (n= 461) 
Enrollment
Fig. 1 Patient disposition in
this trial (2010 CONSORT ﬂow
diagram)
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123Table 2 Effect of lansoprazole on each component of the primary and secondary endpoints
Lansoprazole
a
(n = 226)
Gefarnate
b
(n = 234)
Hazard ratio
(95% CI)
P value
c
Number at risk at baseline
d 213 227
Primary endpoint
Gastric or duodenal ulcer 6 53 0.099 (0.042–0.230) \0.001
Secondary endpoints
Gastric/duodenal ulcer or hemorrhagic lesion 7 56 0.109 (0.050–0.239) \0.001
Gastric/duodenal ulcer, hemorrhagic lesion or
treatment discontinuation due to lack of efﬁcacy
7 59 0.104 (0.047–0.228) \0.001
Component
Gastric ulcer 6 40
Duodenal ulcer 0 15
Hemorrhagic lesion 2 9
Treatment discontinuation due to lack of efﬁcacy 0 4
CI conﬁdence interval
a Patients received lansoprazole 15 mg daily
b Patients received gefarnate 50 mg twice daily
c Log-rank test
d The number of patients at risk included all full-analysis set patients who received at least 1 endoscopy assessment post-randomization, and had
no acute-stage or healing-stage gastric or duodenal ulcer as conﬁrmed by the Independent Adjudication Committee
Table 1 Demographic and
baseline characteristics of
Japanese patients randomized to
treatment
Data are numbers (and % of
total) except where otherwise
indicated
LDA low-dose aspirin, EM
Extensive metabolizers, PM
poor metabolizers
a Those who reported taking
LDA for[3 years prior to the
start of the study medication
were construed as having taken
it for 3 years
b Some patients were included
in more than 1 disease category.
The category ‘‘Others’’ includes
treatments such as carotid
arteriosclerosis or carotid artery
occlusion
c Unknown in 1 patient
d Unknown in 46 patients for
whom consent was not obtained
for the CYP2C19 polymorphism
test
Lansoprazole (n = 226) Gefarnate (n = 235)
Mean age (SD), years 69.3 (8.57) 68.7 (8.79)
Sex
Males 175 (77.4) 192 (81.7)
Females 51 (22.6) 43 (18.3)
Current smoking status 52 (23.0) 53 (22.6)
Alcohol consumption 102 (45.1) 123 (52.3)
Mean duration (SD) of prior LDA (months)
a 25.4 (13.34) 24.9 (13.54)
Status of concomitant aspirin use
Aspirin dialminate 27 (11.9) 28 (11.9)
81 mg 26 (11.5) 26 (11.1)
162 mg 1 (0.4) 3 (1.3)
Aspirin 199 (88.1) 207 (88.1)
100 mg 193 (85.4) 194 (82.6)
200 mg 7 (3.1) 13 (5.5)
Underlying disease
b
Ischemic heart disease 109 (48.2) 120 (51.1)
Ischemic stroke 96 (42.5) 97 (41.3)
Others 50 (22.1) 49 (20.9)
H. pylori status
c
Positive 137 (60.6) 125 (53.2)
Negative 89 (39.4) 109 (46.4)
CYP2C19 polymorphism
d
EM 163 (72.1) 181 (77.0)
PM 40 (17.7) 34 (14.5)
Mean compliance rate (SD), %
Study drug 99.03 (2.268) 98.17 (7.073)
LDA therapy 93.84 (3.319) 93.12 (7.400)
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123lesions at the end of the study was two of the 226 patients
in the lansoprazole group versus nine of the 234 patients in
the gefarnate group. The cumulative incidence rate was
calculated by the Kaplan–Meier method (Supplemental
Fig. 2) and the risk of hemorrhage was shown to be sig-
niﬁcantly lower in the lansoprazole group than in the ge-
farnate group. Bleeding ulcers occurred in one patient in
the lansoprazole group and ﬁve in the gefarnate group.
Other gastric or duodenal bleeding was primarily related to
erosions. The number of patients who were hospitalized
with serious adverse events leading to gastric or duodenal
bleeding was one in the lansoprazole group and ﬁve in the
gefarnate group.
Of the 460 patients randomized to lansoprazole or ge-
farnate in this trial, 262 who had received lansoprazole or
gefarnate were included in an open-label follow-up trial to
examine the outcome after another 24 weeks of treatment
with lansoprazole, in addition to LDA. During this open-
label follow-up trial period, no gastric or duodenal ulcer
recurrence was observed in the study participants
Fig. 2 Kaplan–Meier estimates
of the cumulative incidence of
gastric or duodenal ulcers and
hemorrhagic lesions in the
treatment groups
Table 3 Analysis of subgroups
as deﬁned by each baseline
variable
Data are n/at risk; at risk: the
number of patients at risk
included all full-analysis set
patients who had at least 1 post-
randomization endoscopy
assessment, and had no acute-
stage or healing-stage gastric or
duodenal ulcer as conﬁrmed by
the Independent Adjudication
Committee
EM Extensive metabolizers,
PM Poor metabolizers
a, b, d Results of Cox regression
analyses; hazard ratio (95% CI),
and P value:
a 0.6746
(0.1361–3.3426), P = 0.63;
b 2.2665 (1.2451–4.1258),
P = 0.01;
d 0.6970
(0.3373–1.4405), P = 0.33
c Hazard ratio relative to these
subgroups could not be
estimated
e Could not be estimated
Baseline characteristics Recorded number of patients with gastric or
duodenal ulcer
Cox regression analysis
Lansoprazole Gefarnate Hazard ratio (95% CI) P value
H. pylori status
Positive 3/128
a 38/122
b 0.061 (0.019–0.197) \0.001
Negative 3/85
a 15/105
b 0.206 (0.060–0.710) 0.02
CYP2C19
PM 0/38
c 9/33
d 0.000 (0.000 to –
e)–
EM 5/155
c 39/175
d 0.125 (0.049–0.317) \0.001
Age
32–64 years 1/57 14/72 0.072 (0.009–0.550) 0.02
65–88 years 5/156 39/155 0.106 (0.042–0.268) \0.001
Gender
Male 5/168 43/184 0.104 (0.041–0.264) \0.001
Female 1/45 10/43 0.082 (0.011–0.643) 0.02
Smoker
Yes 1/49 16/51 0.048 (0.006–0.365) 0.01
No 5/164 37/176 0.122 (0.048–0.311) \0.001
Alcohol consumption
Yes 4/96 24/120 0.170 (0.059–0.491) 0.01
No 2/117 29/107 0.052 (0.012–0.219) \0.001
Concomitant use of anticoagulants
Yes 2/47 19/69 0.127 (0.029–0.546) 0.01
No 4/166 34/158 0.091 (0.032–0.256) \0.001
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123(Supplemental Table 1). Importantly, compared to the
ulcer recurrence in the double-blind phase, no ulcer
recurrence was observed from the gefarnate group during
the 6 months of the lansoprazole open study, indicating the
potent preventive effect of lansoprazole.
Adverse events
With respect to adverse events observed in the double-
blind study period (Table 5), diarrhea was noted signiﬁ-
cantly more frequently in the lansoprazole group than in
the gefarnate group, while reﬂux esophagitis occurred
signiﬁcantly more frequently in the gefarnate group. No
serious adverse drug reactions occurred in the lansoprazole
group, versus one (liver disorder) in the gefarnate group.
No deaths occurred in either group. Of the 21 patients who
discontinued lansoprazole, four were suspected of having
possible adverse drug reactions, which included stomatitis,
abnormal liver function tests, diarrhea, constipation, and
palpitation. In the gefarnate group, six patients experienced
possible adverse drug reactions, which included dyspepsia,
Mallory–Weiss syndrome, eczema, tinnitus, toxic skin
eruption, and liver disorder.
From the start of the double-blind study through the
continuedfollow-uptrial, four bone fractures were observed
in four patients in the lansoprazole group, with three events
occurring during the double-blind trial period (P = 0.08,
v
2 test, vs. gefarnate group), and the other one event occur-
ring in the open-label follow-up period. Investigators
reportedthecausesofthebonefracturestobefactorssuchas
aging, accidental fall occurring as a result of a subject’s
inattentiveness, and the like; hence, their causal relationship
tolansoprazolewasdenied.Nobonefractureoccurredinthe
gefarnate group during the double-blind period.
During the entire study, including the follow-up trial,
two deaths occurred, due to ventricular ﬁbrillation and
acute myocardial infarction, respectively; their causal
relationship to lansoprazole was denied by the investiga-
tors. Serious adverse reactions occurred in 51/339 (15.0%)
patients, of which 26 occurred in the follow-up trial.
Of these, melena occurred in one patient (0.3%) and this
was the only event whose causal relationship to lansop-
razole could not be denied. Thirty-nine treatment discon-
tinuations occurred in the entire period; of these, 16
occurred in the follow-up period, where the most common
event was diarrhea, which occurred in four patients (1.2%).
Discussion
Given that no drug has been proven to be effective for the
preventionof gastric orduodenalulcer associated withLDA
therapy in Japan, and given that it is unethical to conduct a
placebo-controlledtrialinpatientsathighriskofdeveloping
gastric or duodenal ulcers, the present study was designed to
compare the efﬁcacy of lansoprazole 15 mg once daily and
gefarnate 50 mg twice daily [11, 12]. Gefarnate is a cyto-
protective anti-ulcer agent which is approved for the treat-
ment of gastric or duodenal ulcers. These cytoprotective
anti-ulcer agents are commonly prescribed as prophylactic
drugs to reduce NSAID- or LDA-induced gastrointestinal
injury, although they have not been investigated in a con-
trolled trial for the latter indication.
To minimize risks to the patients enrolled in this trial,
they were strictly assessed by endoscopic examination for
eligibility. In addition, unlike most long-term clinical trials
conducted to date in a similar patient population, frequent
endoscopic examinations (every 3 or 6 months) were
scheduled by the protocol to closely monitor the study
subjects for early detection of ulcer recurrence.
While there are arguments for and against H. pylori
eradication in long-term NSAID users [14], one study
showed that H. pylori eradication prior to LDA therapy was
equivalent to omeprazole therapy in preventing recurrent
gastrointestinal bleeding [15], although the study was
underpowered to demonstrate such equivalence. However,
in other studies, the ulcerogenic effect of LDA was not
abolished by H. pylori eradication in high-risk patients [7],
and 20% of an entire cohort of patients who had developed
dyspeptic or bleeding ulcers/erosions during prophylactic
Table 4 Results of multivariate
Cox regression analysis using
baseline variables
EM Extensive metabolizers,
PM Poor metabolizers
Baseline characteristics Direction estimation Multivariate analysis
Hazard ratio (95% CI) P value
Treatment group Lansoprazole/gefarnate 0.085 (0.034–0.216) \0.001
H. pylori status Positive/negative 2.057 (1.137–3.720) 0.02
CYP2C19 PM/EM 1.434 (0.668–3.076) 0.36
Age 10 years’ increase 1.459 (1.045–2.036) 0.03
Gender Male/female 0.893 (0.437–1.823) 0.76
Smoking status Yes/no 1.532 (0.820–2.863) 0.19
Alcohol consumption Yes/no 1.047 (0.588–1.866) 0.88
Concomitant use of anticoagulants Yes/no 1.200 (0.665–2.166) 0.55
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123treatment with famotidine were all found to be H. pylori-
negative [10]. Therefore, trial results reported to date are
inconsistent, although H. pylori eradication is generally
recommended in most situations [14, 16]. Besides, because
it was difﬁcult to predict the inﬂuence of rebound acid
hypersecretion occurring after H. pylori eradication [17]o n
the results of the present study, the subjects who required
long-term LDA therapy were not obliged to undergo
H. pylori eradication prior to administration of the study
drug, and the protocol was designed to allow patients to be
treated with a PPI or H. pylori eradication until the day
immediately before the start of treatment with lansoprazole
or gefarnate, given the varying durations of prior LDA use
among the patients. Thus, the study attempted to evaluate
the efﬁcacy of lansoprazole vs. gefarnate against ulcer
recurrences in an ordinary clinical setting, in which
H. pylori eradication was implemented at the discretion of
the attending physician.
Analyses in both H. pylori-positive and -negative sub-
groups in the present study showed ulcer risk reductions in
the lansoprazole group as compared to the gefarnate group,
although the risk reduction rate was higher in the H. pylori-
positive patients. This ﬁnding is consistent with a previous
studyinpatientsatrelativelylowriskforulcercomplications
[8] and supports the usefulness of low-dose lansoprazole in
Japan, where the prevalence of H. pylori infection is high
[18]. Additionally, although more H. pylori-negative
patients will need prophylactic treatment for preventing
Table 5 Frequency of adverse events
Adverse events that occurred in the double-blind period Lansoprazole (n = 226) Gefarnate (n = 234) P value
All adverse events 166 (73.5) 168 (71.8) 0.70
Causal relationship to drug not deniable 26 (11.5) 25 (10.7) 0.78
Leading to discontinuations 21 (9.3) 24 (10.3) 0.73
Serious adverse events 27 (11.9) 26 (11.1) 0.78
Causal relationship to drug not deniable 0 (0.0) 1 (0.4) 0.33
Deaths 0 (0.0) 0 (0.0) –
Adverse events reported in at least 3% of the total in each group
Nasopharyngitis 54 (23.9) 55 (23.5) 0.93
Constipation 14 (6.2) 8 (3.4) 0.17
Fall 13 (5.8) 9 (3.8) 0.34
Diarrhea 19 (8.4) 2 (0.9) \0.001
Reﬂux esophagitis 3 (1.3) 16 (6.8) 0.01
Back pain 10 (4.4) 5 (2.1) 0.17
Elevated blood creatine phosphokinase levels 7 (3.1) 8 (3.4) 0.85
Eczema 5 (2.2) 7 (3.0) 0.61
Hypertension 7 (3.1) 3 (1.3) 0.19
Adverse events reported in patients who received lansoprazole throughout the double-blind
and open-label study
Lansoprazole (n = 339)
All adverse events 279 (82.3)
Causal relationship to drug not deniable 55 (16.2)
Leading to discontinuations 39 (11.5)
Serious adverse events 51 (15.0)
Causal relationship to drug not deniable 1 (0.3)
Deaths 2 (0.6)
Adverse events reported in at least 3% of the total in each group
Nasopharyngitis 113 (33.3)
Diarrhea 32 (9.4)
Constipation 23 (6.8)
Fall 19 (5.6)
Hypertension 17 (5.0)
Elevated blood creatine phosphokinase levels 16 (4.7)
Back pain 16 (4.7)
Table data are numbers (%) of patients in whom an event occurred at least 1 time during the trial
732 J Gastroenterol (2011) 46:724–735
123LDA ulcers in Japan, where the H. pylori infection rate is
predicted to gradually decrease [19], low-dose lansoprazole
should still be effective in these patients as well.
A ﬁnal analysis of the study data showed that lansop-
razole produced a 90.1% reduction in the risk of ulcer
recurrence, which was highly signiﬁcant. The reduction
rate is similar to that in a placebo-controlled study con-
ducted in Hong Kong in patients taking LDA [7] and even
higher than that in another study in patients with ulcers
associated with LDA, where the rate of risk reduction was
found to be about 70% [8].
Althoughtherecurrenceofulcersobservedbyendoscopy
was assessed as the primary endpoint in the present study,
other clinical endpoints, such as gastrointestinal bleeding
and patient hospitalization,were also compared between the
treatment groups, because these true clinical outcomes are
very important in evaluating the drugs for efﬁcacy. In this
study,morepatientsinthegefarnategroupdevelopedgastric
or duodenal hemorrhagic lesions and were hospitalized with
serious adverse events leading to gastric or duodenal
bleeding. Thus, overall, lansoprazole was superior to gefar-
nate in all endpoints assessed in this study.
Furthermore, there were no new-onset ulcers noted in
the additional 6 months’ follow-up trial, supporting the
idea that lansoprazole provides superior long-term efﬁcacy
in preventing LDA-associated gastric/duodenal ulcers,
compared to gefarnate.
Of note, the present study represents the longest follow-
up (18 months or more) of patients with a deﬁnite history
of gastric or duodenal ulcer who required long-term LDA
therapy, of all reports (3–12 months) published in the
literature [7–10].
Thus, lansoprazole appears to have an important role to
play in reducing the risk of gastroduodenal ulcers in patients
athighriskofdevelopingulcerswhorequirelong-termLDA
therapy due to cardiovascular and cerebrovascular disease,
while at the same time allowing such antiplatelet therapy to
reduce thromboembolic events in these patients.
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Shinojima, Hokkaido Health Coop Ryokuai Hospital,
Sapporo, Hokkaido; Masao Yamauchi, Yamauchi Medical
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Sendai Medical Center, Sendai, Miyagi; Hitoshi Sekine,
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Tohoku Kosei-Nenkin Hospital, Sendai, Miyagi; Yasushi
Matsumoto, Kohnan Hospital, Sendai, Miyagi; Masaharu
Kanazawa, Sendai Open Hospital, Sendai, Miyagi; Masa-
hiro Yagi, Sendai Cardiovascular Disease Center, Sendai,
Miyagi; Mutsumi Nozue, Shonai Amakume Hospital,
Amakume, Yamagata; Yuji Mizokami, Tokyo Medical
University Ibaraki Medical Center, Kasumigauwa, Ibaraki;
Shuichi Taguchi, Mito Medical Center, Mito, Ibaraki;
Naoko Moriyama, Kasumigaura Medical Center, Kasumi-
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Ayabe Medical Clinic, Hitachinaka, Ibaraki; Kentaro
Sugano, Jichi Medical University Hospital, Shimotsuke,
Tochigi; Hideki Nagaoka, Fujioka General Hospital Out-
patient Center, Fujioka, Gunma; Syunroku Sugimoto,
Sugimoto Hospital, Maebashi, Gunma; Tadahiko Kubo,
Hanyu General Hospital, Hanyu, Gunma; Kazuyoshi
Harano, Yotsukaido Tokushukai Medical Center, Yotsukaido,
Chiba; Masahiro Yoshioka, Minamitama Hospital,
Hachioji, Tokyo; Kazuhiko Segawa, National Hospital
Organization Tokyo Hospital, Kiyose, Tokyo; Terunao
Ashida, The Institute for Adult Disease, Marunouchi
Hospital, Chiyoda-ku, Tokyo; Naomi Uemura, National
Center for Global Health and Medicine, Shinjuku-ku,
Tokyo; Masao Matsumoto, Tokyo Kosei Nenkin Hospital,
Shinjuku-ku, Tokyo; Makoto Akaishi, Kitasato Institute
Hospital, Minato-ku, Tokyo; Nobuyuki Matsuhashi, Nip-
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Shinagawa-ku, Tokyo; Hisakuni Sekino, Sekino Hospital,
Toshima-ku, Tokyo; Jun Hashida, Eisei Clinic, Hachioji,
Tokyo; Shigeto Kiyokawa, Fujimori Clinic, Hachioji,
Tokyo; Yoshio Ohashi, Ekimae Building Clinic, Chuo-ku,
Tokyo; Atsushi Takahashi, Yokosuka Kyosai Hospital,
Yokosuka, Kanagawa; Takahiro Takei, Fujisawa
J Gastroenterol (2011) 46:724–735 733
123Shounandai Hospital, Fujisawa, Kanagawa; Satoshi Kiy-
ama, Chuo-Rinkan Hospital, Yamato, Kanagawa; Hitoshi
Ohishi, Saiseikai Yokohama-shi Nanbu Hospital, Yoko-
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Ishikawa; Kouji Shinmura, Shinmura Hospital, Shiroyama,
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Fukui; Toshiyuki Noda, Gifu Prefectural General Medical
Center, Gifu, Gifu; Masatoshi Koshiji, Gifu Central Hos-
pital, Gifu, Gifu; Takuya Umemoto, National Hospital
Organization Shizuoka Medical Center, Shunto-gun, Shi-
zuoka; Mashio Nakamura, Mie University Hospital, Tsu,
Mie; Makoto Kuroda, Matsusaka City Hospital, Matsusaka,
Mie; Hitoshi Yoshimura, Mie Prefectural Shima Hospital,
Shima, Mie; Osamu Yamaoka, Social Insurance Shiga
Hospital, Otsu, Shiga; Tateo Sugiyama, Kanai Hospital,
Kyoto, Kyoto; Yasumasa Kondo, Horikawa Hospital,
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Matsubara, Osaka; Shinya Ohashi, Kitano Hospital, Osaka,
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Osaka, Osaka; Kiyotaka Ookawa, Osaka Municipal Gen-
eral Medical Center, Osaka, Osaka; Takashi Abe, Osaka
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Nishinomiya Kyoritsu Neusurgical Hospital, Nishinomiya,
Hyogo; Hiroyuki Ogawa, Nishinomiya Municipal Central
Hospital, Nishinomiya, Hyogo; Hirofumi Okada, National
Hospital Organization Hamada Medical Center, Hamada,
Shimane; Hiroshi Mieno, Hiroshima General Hospital of
the West Japan Railway Company, Hiroshima, Hiroshima;
Hiroaki Oogoshi, Hiroshima City Asa Hospital, Hiroshima,
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Shin-Mizumaki Hospital, Onga-gun, Fukuoka; Yasuhiro
Morikami, Kumamoto City Hospital, Kumamoto, Kuma-
moto; Yoshihiro Kimura, Kumamoto City Hospital,
Kumamoto, Kumamoto; Kazuhiro Sugi, National Hospital
Organization Kumamoto Medical Center, Kumamoto,
Kumamoto; Tatsuhiko Ooie, National Hospital Organiza-
tion Oita Medical Center, Oita, Oita; Masahiro Yoshinaga,
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Koga General Hospital, Miyazaki, Miyazaki; Yoshihide
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